These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28355723)

  • 1. [A cross-sectional study on application of glucocorticoid in systemic lupus erythematosus patients].
    Xu LL; Guo QY; Cai XY; Da ZY; Zhu HQ; Zhang LY; Su Y
    Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):290-294. PubMed ID: 28355723
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.
    Ruiz-Arruza I; Ugarte A; Cabezas-Rodriguez I; Medina JA; Moran MA; Ruiz-Irastorza G
    Rheumatology (Oxford); 2014 Aug; 53(8):1470-6. PubMed ID: 24681836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
    Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
    Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.
    Tarr T; Papp G; Nagy N; Cserép E; Zeher M
    Clin Rheumatol; 2017 Feb; 36(2):327-333. PubMed ID: 27889859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
    Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
    Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN; Liu CS; Tsai TR; Hung YC; Chang SJ; Lin HL; Chen YC; Lai HM; Yu SF; Chen CJ
    Kaohsiung J Med Sci; 2011 Jul; 27(7):251-7. PubMed ID: 21757141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
    Mease PJ; Ginzler EM; Gluck OS; Schiff M; Goldman A; Greenwald M; Cohen S; Egan R; Quarles BJ; Schwartz KE
    J Rheumatol; 2005 Apr; 32(4):616-21. PubMed ID: 15801015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study.
    Ruiz-Arruza I; Lozano J; Cabezas-Rodriguez I; Medina JA; Ugarte A; Erdozain JG; Ruiz-Irastorza G
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):582-591. PubMed ID: 28704598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of long-term low dose prednisone on bone mineral density in patients with systemic lupus erythematosus].
    Wang G; Li XP; Li XM; Wang GS; Tao JH; Ma Y
    Zhonghua Nei Ke Za Zhi; 2017 Mar; 56(3):179-183. PubMed ID: 28253597
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistent glucocorticoid resistance in systemic lupus erythematosus patients during clinical remission.
    Melo AK; Melo MR; Saramago AB; Demartino G; Souza BD; Longui CA
    Genet Mol Res; 2013 Jun; 12(2):2010-9. PubMed ID: 23479142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of glucocorticoid receptor isoforms and associations with serine/arginine-rich protein 30c and 40 in patients with systemic lupus erythematosus.
    Guan YC; Jiang L; Ma LL; Sun XN; Yu DD; Liu J; Qu DX; Fang MY
    Clin Exp Rheumatol; 2015; 33(2):225-33. PubMed ID: 25665148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases.
    Morel N; Bonjour M; Le Guern V; Le Jeunne C; Mouthon L; Piette JC; Costedoat-Chalumeau N
    Lupus; 2015 Dec; 24(14):1479-85. PubMed ID: 26163661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
    Ruiz-Irastorza G; Ugarte A; Saint-Pastou Terrier C; Lazaro E; Iza A; Couzi L; Saenz R; Richez C; Porta S; Blanco P
    Autoimmun Rev; 2017 Aug; 16(8):826-832. PubMed ID: 28564619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
    Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
    Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
    Ugarte A; Danza A; Ruiz-Irastorza G
    Curr Opin Rheumatol; 2018 Sep; 30(5):482-489. PubMed ID: 29870497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort.
    Zahr ZA; Fang H; Magder LS; Petri M
    Lupus; 2013 Jun; 22(7):697-701. PubMed ID: 23708944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus.
    Sarkissian T; Beyene J; Feldman B; McCrindle B; Silverman ED
    Arthritis Rheum; 2007 Feb; 56(2):631-8. PubMed ID: 17265498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs.
    Chen SY; Choi CB; Li Q; Yeh WS; Lee YC; Kao AH; Liang MH
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1086-94. PubMed ID: 25732795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
    Dittrich K; Ross S; Benz K; Amann K; Dötsch J
    Klin Padiatr; 2009 Dec; 221(7):425-9. PubMed ID: 20013565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.